Screener
Travere Therapeutics, Inc. TVTX Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| License and collaboration revenue | 2,707 | 5,871 |
| Total revenue | 127,199 | 81,732 |
| Operating expenses: | ||
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s total cost of revenue?
- Travere Therapeutics, Inc. (TVTX) reported total cost of revenue of $1.95M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total cost of revenue changed year-over-year?
- Travere Therapeutics, Inc.'s total cost of revenue decreased by 58.3% year-over-year, from $4.68M to $1.95M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total cost of revenue?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s total cost of revenue has grown at a 18.8% compound annual growth rate (CAGR), from $6.17M to $10.34M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Travere Therapeutics, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude